Data / Form D filings / Aviceda Therapeutics, Inc.
Aviceda Therapeutics, Inc.: Form D filings
Aviceda Therapeutics, Inc., a biotechnology company in Cambridge, MA, filed 8 Form D notices with the SEC between 2020 and 2025. The latest, on January 13, 2025, reports $75 million sold of a $207.5 million offering to 17 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ONE BROADWAY, 14TH FLOOR, Cambridge, MA, 02142
- Phone
- (617) 332-0741
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1824762
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 13, 2025 | Amendment | $207,499,882 | $74,999,940 | $132,499,942 | 17 | Dec 17, 2024 | sec.gov |
| Nov 22, 2024 | New notice | $200,000,000 | $0 | $200,000,000 | 0 | Yet to occur | sec.gov |
| May 31, 2024 | New notice | $27,700,000 | $18,899,969 | $8,800,031 | 18 | May 17, 2024 | sec.gov |
| May 19, 2023 | New notice | $15,610,000 | $15,610,000 | 11 | May 5, 2023 | sec.gov | |
| Mar 28, 2022 | New notice | $26,200,000 | $8,398,584 | $17,801,416 | 16 | Mar 11, 2022 | sec.gov |
| Mar 28, 2022 | New notice | $79,700,000 | $49,450,983 | $30,249,017 | 11 | Mar 16, 2022 | sec.gov |
| Aug 12, 2021 | New notice | $1,950,000 | $1,950,000 | 7 | Jul 14, 2021 | sec.gov | |
| Sep 16, 2020 | New notice | $4,250,000 | $4,250,000 | 15 | Feb 26, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| David Callanan | Executive Officer | |
| Nancy Thomason | Director | |
| Mohamed Genead | Executive Officer, Director | |
| Michael Tolentino | Executive Officer, Director | |
| Christoph Adams | Director | |
| Tarek Hassan | Executive Officer | |
| Erin Lavelle | Director | |
| David Guyer | Director | |
| Derek Kunimoto | Executive Officer | |
| Jay Woods | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Jan 13, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Aviceda Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.